Treatment of Well-Differentiated Gastric Neuroendocrine Tumor (NET)

This protocol addresses patients with a well-differentiated gastric neuroendocrine tumor (NET) of the gastrointestinal tract — a clinically and biologically distinct category from poorly differentiated neuroendocrine carcinoma (NEC), which follows a separate management pathway.

Clinical scenario: Well-differentiated gastric NET of the gastrointestinal tract. Correct histological classification — confirming the tumor is well-differentiated (NET) rather than poorly differentiated (NEC) — is a prerequisite for applying this protocol, as the two entities are managed differently.

The protocol incorporates a molecular targeted drug approach for tumor control. The full regimen, eligibility criteria, and supporting evidence are contained within the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s00535-021-01827-7

The WHO Classification of Endocrine Organs (2017) and Digestive System (2019) categorizes NENs as well-differentiated NENs (termed “NETs”) or poorly differentiated NECs.

Regarding molecular targeted drugs, insurance covers everolimus and sunitinib for pancreatic NETs as well as everolimus for gastrointestinal NETs.

View source ↗